Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases
摘要:
Dual CYP17/CYP11B2 inhibitors are proposed as a novel strategy for the treatment of prostate cancer to reduce risks of cardiovascular diseases. Via a combination of ligand- and structure-based approaches, a series of dual inhibitors were designed leading to the 2-(3-pyridyl)naphthalenes 10 and 11 with strong inhibition of both enzymes (IC50 values around 20 nM) and excellent selectivities over CYP11B1, CYP19, and CYP3A4. These compounds are considered as promising candidates for further in vivo evaluation.
halonaphthols with benzyl/allylbromides is described. Halonaphthols are used as carbon-nucleophiles in dearomatization to form three-dimensional cyclic enones with excellent chemoselectivity, in which etherification of phenolic hydroxyl group could be restrained well by using cesium carbonate as the base. A wide range of cyclic enones is directly prepared from various substituted benzyl/allylbromides and halonaphthols
描述了卤代萘酚与苄基/烯丙基溴的第一次分子间亲电脱芳构化。卤代萘酚作为碳亲核试剂在脱芳构化中形成具有优异化学选择性的三维环状烯酮,其中以碳酸铯为碱可以很好地抑制酚羟基的醚化。从各种取代的苄基/烯丙基溴和卤代萘酚直接制备出范围广泛的环状烯酮。机理研究表明直接的 S N 2 反应途径。
Decarboxylative Fluorination of Arylcarboxylic Acids Promoted by <i>ortho</i>
-Hydroxy and Amino Groups
作者:Dinghai Wang、Zheliang Yuan、Qilun Liu、Pinhong Chen、Guosheng Liu
DOI:10.1002/cjoc.201800016
日期:2018.6
A novel decarboxylative fluorination process has been developed for the synthesis of ortho‐hydroxy/amino arylfluorides from salicylic acid analogs, in which the ortho‐hydroxy/amino group plays an important role in the transformation. In addition, various arylfluorides are obtained in good to excellent yields under mild conditions.
Highly Potent and Selective Nonsteroidal Dual Inhibitors of CYP17/CYP11B2 for the Treatment of Prostate Cancer To Reduce Risks of Cardiovascular Diseases
作者:Mariano A. E. Pinto-Bazurco Mendieta、Qingzhong Hu、Matthias Engel、Rolf W. Hartmann
DOI:10.1021/jm400484p
日期:2013.8.8
Dual CYP17/CYP11B2 inhibitors are proposed as a novel strategy for the treatment of prostate cancer to reduce risks of cardiovascular diseases. Via a combination of ligand- and structure-based approaches, a series of dual inhibitors were designed leading to the 2-(3-pyridyl)naphthalenes 10 and 11 with strong inhibition of both enzymes (IC50 values around 20 nM) and excellent selectivities over CYP11B1, CYP19, and CYP3A4. These compounds are considered as promising candidates for further in vivo evaluation.